4//SEC Filing
SGX PHARMACEUTICALS, INC. 4
Accession 0001233840-08-000021
CIK 0001125603operating
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 5:11 PM ET
Size
17.9 KB
Accession
0001233840-08-000021
Insider Transaction Report
Form 4
BVF PARTNERS L P/IL
10% OwnerOther
Transactions
- Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−3,250,200$9,750,600→ 0 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−914,700$2,744,100→ 3,250,200 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−1,342,774$4,028,322→ 4,164,900 total(indirect: See footnotes)
BIOTECHNOLOGY VALUE FUND L P
10% OwnerOther
Transactions
- Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−3,250,200$9,750,600→ 0 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−1,342,774$4,028,322→ 4,164,900 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−914,700$2,744,100→ 3,250,200 total(indirect: See footnotes)
BIOTECHNOLOGY VALUE FUND II LP
10% OwnerOther
Transactions
- Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−3,250,200$9,750,600→ 0 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−914,700$2,744,100→ 3,250,200 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−1,342,774$4,028,322→ 4,164,900 total(indirect: See footnotes)
BVF INVESTMENTS LLC
10% OwnerOther
Transactions
- Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−914,700$2,744,100→ 3,250,200 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−3,250,200$9,750,600→ 0 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−1,342,774$4,028,322→ 4,164,900 total(indirect: See footnotes)
BVF INC/IL
10% OwnerOther
Transactions
- Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−1,342,774$4,028,322→ 4,164,900 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−3,250,200$9,750,600→ 0 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2008-08-20$3.00/sh−914,700$2,744,100→ 3,250,200 total(indirect: See footnotes)
Footnotes (8)
- [F1]The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments.
- [F2]Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.
- [F3]Shares directly beneficially owned by BVF, L.P.
- [F4]Shares directly beneficially owned by BVF2, L.P.
- [F5]Shares directly beneficially owned by Investments.
- [F6]Total amount of shares indirectly beneficially owned by Partners and BVF Inc.
- [F7]Disposed of pursuant to The Purchase and Plan of Merger dated July 8, 2008 by and among the issuer, Eli Lilly and Company and REM Merger Sub, Inc. (the "Merger Agreement").
- [F8]Disposed of pursuant to the Merger Agreement in exchange for $3.00 for each share of SGX Pharmaceuticals, Inc. common stock held by the Reporting Persons.
Documents
Issuer
SGX PHARMACEUTICALS, INC.
CIK 0001125603
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001125603
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 5:11 PM ET
- Size
- 17.9 KB